Top

Cancer Chemotherapy and Pharmacology

Published in:

01-09-2018 | Original Article

Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer

Authors: Xiao-fang Guo, Sai-sai Li, Xiao-fei Zhu, Qiao-hua Dou, Duan Liu

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2018

Abstract

Purpose

Paclitaxel-based chemoradiotherapy was proven to be efficacious in treating patients with advanced esophageal cancer. However, the toxicity and the development of resistance limited its anticancer efficiency. The present study was to evaluate the antitumor effects of lapatinib, a dual tyrosine inhibitor of both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), combined with paclitaxel on the esophageal squamous cancer.

Methods

MTT assays were used to evaluate the effects of the combination of lapatinib and paclitaxel on the growth of esophageal squamous cancer cell lines (KYSE150, KYSE450, KYSE510 and TE-7). The activity of the combination of two agents on cell invasion, migration and apoptosis was measured by wound healing assay, transwell assay and Annexin V-FITC/PI stain assay. Western blot assay was used to analyze the effects of the two agents on the EGFR/HER2 signaling. The in vivo efficacy was evaluated in KYSE450 xenograft nude mouse model.

Results

The combination of lapatinib and paclitaxel was highly synergistic in inhibiting cell growth with a combination index of < 1, and suppressed significantly the invasion and migration capability of esophageal squamous cancer cells. Esophageal squamous cancer cells displayed increased rates of apoptosis after treatment with lapatinib plus paclitaxel. The phosphorylated EGFR and HER2 as well as the activation of downstream molecules MAPKs and AKT significantly decreased when exposed to lapatinib and paclitaxel. In vivo studies showed that the combination of two agents had greater antitumor efficacy than either agent alone.

Conclusions

The combination of lapatinib with paclitaxel showed synergistic antitumor activity, suggesting their potential in treating patients with esophageal squamous cancer.

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H et al (1984) The global burden of cancer 2013. JAMA Oncol 1:505–527. https://doi.org/10.1001/jamaoncol.2015.0735 CrossRef

Wang AH, Liu Y, Wang B, He YX, Fang YX, Yan YP (2014) Epidemiological studies of esophageal cancer in the era of genome-wide association studies. World J Gastrointest Pathophysiol 5:335–343. https://doi.org/10.4291/wjgp.v5.i3.335 CrossRefPubMedPubMedCentral

Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á (2015) Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol 21:7933–7943. https://doi.org/10.3748/wjg.v21.i26.7933 CrossRefPubMedPubMedCentral

Bystricky B, Okines AF, Cunningham D (2011) Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 71:541–555. https://doi.org/10.2165/11585460-000000000-00000 CrossRefPubMed

Mariette C, Piessen G, Triboulet JP (2007) Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 8:545–553. https://doi.org/10.1016/S1470-2045(07)70172-9 CrossRefPubMed

Lagergren J, Smyth E, Cunningham D, Lagergren P (2017) Oesophageal cancer. Lancet 390:2383–2396. https://doi.org/10.1016/S0140-6736(17)31462-9 CrossRefPubMed

Neuner G, Patel A, Suntharalingam M (2009) Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res 3:57–65. https://doi.org/10.1080/17512433.2017.1313112 PubMedPubMedCentralCrossRef

Tomasello G, Ghidini M, Barni S, Passalacqua R, Petrelli F (2017) Overview of different available chemotherapy regimens combined with radiotherapy for the neoadjuvant and definitive treatment of esophageal cancer. Expert Rev Clin Pharmacol 10:649–660. https://doi.org/10.1080/17512433.2017.1313112 CrossRefPubMed

Imai H, Komine K, Takahashi S et al (2016) Efficacy and safety assessment of paclitaxel in patients with docetaxel-resistant esophageal squamous cell carcimona. Chemotherapy 61:262–268. https://doi.org/10.1159/000444122 CrossRefPubMed

10.

Liu Y, Ren Z, Yuan L, Xu S, Yao Z, Qiao L, Li K (2016) Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. Am J Cancer Res 6:2345–2350PubMedPubMedCentral

11.

Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99–110CrossRefPubMed

12.

Gibault L, Metges JP, Conan-Charlet V, Lozac’h P, Robaszkiewicz M, Bessaguet C, Lagarde N, Volant A (2005) Diffuse EGFR staining is associated with reduced overall survival in locally advanced esophageal squamous cell cancer. Br J Cancer 93:107–115. https://doi.org/10.1038/sj.bjc.6602625 CrossRefPubMedPubMedCentral

13.

Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS (2000) Her-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol 31:35–39CrossRefPubMed

14.

Reddy D, Wainberg ZA (2011) Targeted therapies for metastatic esophagogastric cancer. Curr Treat Options Oncol 12:46–60. https://doi.org/10.1007/s11864-011-0138-4 CrossRefPubMedPubMedCentral

15.

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743. https://doi.org/10.1056/NEJMoa064320 CrossRefPubMed

16.

Kondo N, Tsukuda M, Ishiguro Y, Kimura M, Fujita K, Sakakibara A, Takahashi H, Toth G, Matsuda H (2010) Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 23:957–963CrossRefPubMed

17.

Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16:1509–1519. https://doi.org/10.1158/1078-0432.CCR-09-1112 CrossRefPubMed

18.

McHugh LA, Sayan AE, Mejlvang J, Griffiths TR, Sun Y, Manson MM, Tulchinsky E, Mellon JK, Kriajevska M (2009) Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells. Int J Oncol 34:1155–1163PubMed

19.

Shiraishi K, Mimura K, Izawa S et al (2013) Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer 16:571–580. https://doi.org/10.1007/s10120-012-0219-5 CrossRefPubMed

20.

Powles T, Huddart RA, Elliott T et al (2017) Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1/2-positive metastatic bladder cancer. J Clin Oncol 35: 48–55. https://doi.org/10.1200/JCO.2015.66.3468 CrossRefPubMed

21.

Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999–3005. https://doi.org/10.1200/JCO.2007.14.0590 CrossRefPubMed

22.

Lorenzen S, Riera Knorrenschild J, Haag GM et al (2015) Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer 51:569–576. https://doi.org/10.1016/j.ejca.2015.01.059 CrossRefPubMed

23.

Guo XF, Zhu XF, Zhong GS, Deng BG, Gao ZT, Wang H (2012) Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Oncol Rep 27:1639–1645. https://doi.org/10.3892/or.2012.1659 CrossRefPubMed

24.

Tanizaki J, Okamoto I, Takezawa K, Tsukioka S, Uchida J, Kiniwa M, Fukuoka M, Nakagawa K (2010) Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification. Mol Cancer Ther 9:1198–1207. https://doi.org/10.1158/1535-7163.MCT-10-0045 CrossRefPubMed

25.

Okines A, Cunningham D, Chau I (2011) Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 8:492–503. https://doi.org/10.1038/nrclinonc.2011.45 CrossRefPubMed

26.

Kavallaris M (2010) Microtubules and resistance to tubulin binding agents. Nat Rev Cancer 10:194–204. https://doi.org/10.1038/nrc2803 CrossRefPubMed

27.

Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086–1091CrossRefPubMed

28.

Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, Imamoto H, Amano N, Seriu T (2011) A phase II study of PTX biweekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum based chemotherapy. Cancer Chemother Pharmacol 67:1265–1272. https://doi.org/10.1007/s00280-010-1422-x CrossRefPubMed

29.

Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A (2002) Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 86:669–673. https://doi.org/10.1038/sj.bjc.6600166 CrossRefPubMedPubMedCentral

30.

Tishler RB, Schiff PB, Geard CR, Hall EJ (1992) Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613–617CrossRefPubMed

31.

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed

32.

Ando N, Iizuka T, Ide H et al (2003) Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol 21:4592–4596. https://doi.org/10.1200/JCO.2003.12.095 CrossRefPubMed

33.

Ilson DH (2008) Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res 2:85–92PubMedPubMedCentral

34.

Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968–3976. https://doi.org/10.1200/JCO.2011.36.2236 CrossRefPubMed

35.

Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X CrossRefPubMed

36.

Suntharalingam M, Winter K, Ilson D et al (2017) Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol 3:1520–1528. https://doi.org/10.1001/jamaoncol.2017.1598 CrossRefPubMedPubMedCentral

37.

Dragovich T, McCoy S, Fenoglio-Preiser CM et al (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24: 4922–4927. https://doi.org/10.1200/JCO.2006.07.1316 CrossRefPubMed

38.

Kwak EL, Jankowski J, Thayer SP et al (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283–4287. https://doi.org/10.1158/1078-0432.CCR-06-0189 CrossRefPubMedPubMedCentral

39.

Cappuzzo F, Varella-Garcia M, Shigematsu H et al (2005) Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23:5007–5018. https://doi.org/10.1200/JCO.2005.09.111 CrossRefPubMed

40.

Hecht JR, Bang YJ, Qin SK et al (2016) Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. J Clin Oncol 34:443–451. https://doi.org/10.1200/JCO.2015.62.6598 CrossRefPubMed

41.

Hou W, Qin X, Zhu X et al (2013) Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models. Oncol Rep 30:707–714. https://doi.org/10.3892/or.2013.2500 CrossRefPubMed

42.

McHugh LA, Kriajevska M, Mellon JK, Griffiths TR (2007) Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens—evidence of schedule-dependent synergy. Urology 69:390–394. https://doi.org/10.1016/j.urology.2006.12.003 CrossRefPubMed

Title: Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer
Authors: Xiao-fang Guo
Sai-sai Li
Xiao-fei Zhu
Qiao-hua Dou
Duan Liu
Publication date: 01-09-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3627-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation

A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors

Brazilin induces FOXO3A-dependent autophagic cell death by disturbing calcium homeostasis in osteosarcoma cells

A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer